Rosalind Rei
Reporter
Rosalind Rei has a background in science communication and business journalism. Before joining Generics Bulletin in 2022, she worked as a freelance writer and researcher covering sustainability, biotech, biomaterials, climate science, and carbon finance. She has also written and produced episodes on the history of science for the Harvard-based podcast Ministry of Ideas.
She holds a master’s in the history and philosophy of science and takes keen interests in political economy, ecology, and environment.
Latest From Rosalind Rei
Glenmark’s Ryaltris Set To Hit Canadian Market
Health Canada approves Ryaltris for allergic rhinitis, opening up yet another major market for Glenmark’s branded specialty medicine. Bausch Health will sell the drug in Canada.
Stada’s Rare Kidney Disease Drug Is EU First
Stada advances its Specialty ambitions by launching the EU’s first authorized treatment for the rare kidney disease immunoglobulin A nephropathy in the form of its modified-release budesonide capsules.
Akorn's Delay Moving Three Generics To OTC Leads To $7.9M Settlement In Medicare Billing Complaint
Akorn agrees with DoJ to pay $7.9m to settle allegations it deliberately sold three as Rx three ingredients moved to OTC. Mislabeling led Medicare Part D to pay for the drugs for around a year despite the products not being eligible for coverage.
Formycon Reveals Keytruda Biosimilar In The Works
Formycon has revealed that pembrolizumab is one of its six biosimilars in development. The blockbuster reference biologic Keytruda brought in $17.2bn for Merck & Co. in 2021.
Akorn Pays Out $7.9m In Medicare Fraudulent Billing Case
Akorn has agreed to pay out $7.9m to settle allegations that it deliberately sold three generic drugs as prescription-only when they should have been classed as over-the-counter, in a deal with the US Department of Justice. The mislabeling led Medicare Part D to pay out for the drugs for around a year despite the products not being eligible for Medicare coverage.
Civica’s $27.8m New Facility Expands Virginia Drug Hub Vision
Civica has announced a further $27.8m investment to support its plans for insulin and other essential medicines. The news comes shortly after CivicaScript announced its first launch in the form of abiraterone tablets.